Literature DB >> 25015937

Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.

Jessica Liegel1, Elizabeth Courville2, Zohar Sachs1, Celalettin Ustun3.   

Abstract

Entities:  

Keywords:  myeloid maturation; sorafenib; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2014        PMID： 25015937      PMCID： PMC4222467          DOI： 10.3324/haematol.2014.109975

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases.

Authors:  E Colombo; M Alcalay; P G Pelicci
Journal:  Oncogene       Date:  2011-01-31       Impact factor: 9.867

2.  Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.

Authors:  Sarah Guenounou; Eric Delabesse; Christian Récher
Journal:  Eur J Haematol       Date:  2014-04-18       Impact factor: 2.997

Review 3.  Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?

Authors:  Brunangelo Falini; Maria Paola Martelli; Niccolò Bolli; Paolo Sportoletti; Arcangelo Liso; Enrico Tiacci; Torsten Haferlach
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

4.  A quantitative analysis of kinase inhibitor selectivity.

Authors:  Mazen W Karaman; Sanna Herrgard; Daniel K Treiber; Paul Gallant; Corey E Atteridge; Brian T Campbell; Katrina W Chan; Pietro Ciceri; Mindy I Davis; Philip T Edeen; Raffaella Faraoni; Mark Floyd; Jeremy P Hunt; Daniel J Lockhart; Zdravko V Milanov; Michael J Morrison; Gabriel Pallares; Hitesh K Patel; Stephanie Pritchard; Lisa M Wodicka; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2008-01       Impact factor: 54.908

5.  High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

Authors:  S K Metzelder; T Schroeder; A Finck; S Scholl; M Fey; K Götze; Y C Linn; M Kröger; A Reiter; H R Salih; T Heinicke; R Stuhlmann; L Müller; A Giagounidis; R G Meyer; W Brugger; M Vöhringer; P Dreger; M Mori; N Basara; K Schäfer-Eckart; B Schultheis; C Baldus; A Neubauer; A Burchert
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

Review 6.  Mutant FLT3 signaling contributes to a block in myeloid differentiation.

Authors:  Rui Zheng; Donald Small
Journal:  Leuk Lymphoma       Date:  2005-12

Review 7.  FLT3 mutations: biology and treatment.

Authors:  Donald Small
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2006

8.  Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Authors:  Rui Zheng; Alan D Friedman; Mark Levis; Li Li; Edward G Weir; Donald Small
Journal:  Blood       Date:  2003-10-30       Impact factor: 22.113

Review 9.  The roles of FLT3 in hematopoiesis and leukemia.

Authors:  D Gary Gilliland; James D Griffin
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

10.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113
View more
  7 in total

1.  Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia.

Authors:  Hyun Don Yun; Sunita Nathan; Melissa Larson; Mohammad J Hussain; Deborah A Katz; Ankur Varma; Ira Miller; Celalettin Ustun
Journal:  Blood Adv       Date:  2019-11-26

2.  High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive In Vitro Kinase Assay Substrates.

Authors:  Minervo Perez; John Blankenhorn; Kevin J Murray; Laurie L Parker
Journal:  Mol Cell Proteomics       Date:  2018-12-12       Impact factor: 5.911

3.  High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.

Authors:  Hsiao-Wen Kao; D Cherng Liang; Ming-Chung Kuo; Jin-Hou Wu; Po Dunn; Po-Nan Wang; Tung-Liang Lin; Yu-Shu Shih; Sung-Tzu Liang; Tung-Huei Lin; Chen-Yu Lai; Chun-Hui Lin; Lee-Yung Shih
Journal:  Oncotarget       Date:  2015-10-20

4.  Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.

Authors:  C Ustun; F Giannotti; M-J Zhang; H-L Wang; C Brunstein; M Labopin; V Rocha; M de Lima; F Baron; B M Sandmaier; M Eapen; E Gluckman; A Nagler; D J Weisdorf; A Ruggeri
Journal:  Leukemia       Date:  2017-01-25       Impact factor: 11.528

Review 5.  The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant.

Authors:  Grace Xiuqing Li; Lan Wang; Bassam Yaghmour; Giridharan Ramsingh; George Yaghmour
Journal:  Leuk Res Rep       Date:  2018-07-19

6.  The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult.

Authors:  Yeohan Song; Dale Bixby; Diane Roulston; John Magenau; Sung Won Choi
Journal:  J Leuk (Los Angel)       Date:  2014

Review 7.  Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Authors:  Ali Bazarbachi; Gesine Bug; Frederic Baron; Eolia Brissot; Fabio Ciceri; Iman Abou Dalle; Hartmut Döhner; Jordi Esteve; Yngvar Floisand; Sebastian Giebel; Maria Gilleece; Norbert-Claude Gorin; Elias Jabbour; Mahmoud Aljurf; Hagop Kantarjian; Mohamed Kharfan-Dabaja; Myriam Labopin; Francesco Lanza; Florent Malard; Zinaida Peric; Thomas Prebet; Farhad Ravandi; Annalisa Ruggeri; Jaime Sanz; Christoph Schmid; Roni Shouval; Alexandros Spyridonidis; Jurjen Versluis; Norbert Vey; Bipin N Savani; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2020-04-02       Impact factor: 9.941
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.